February 2026 in “Clinical Cosmetic and Investigational Dermatology” This study highlights how combining genetic and environmental risk assessments could advance early screening and personalized prevention for vitiligo, given its genetic complexity and environmental interactions.
January 2026 in “Dermatology Practical & Conceptual” In this study, pediatric alopecia areata was associated with higher rates of vitiligo, asthma, and ADHD, and significantly lower levels of vitamin B12, ferritin, and TSH compared to healthy controls, highlighting the need for comprehensive evaluation.
January 2026 in “Dermatology and Therapy” This study suggests a possible bidirectional relationship between sleep quality and hair loss, indicating that addressing sleep disturbances might improve hair loss management and patient well-being.
January 2026 in “Immune Network” This review discusses the heterogeneity of Tregs in normal and tumor environments, emphasizing the complexity of targeting tumor-resident Tregs while maintaining systemic immune tolerance, but reports no new findings.
December 2025 in “ADMET & DMPK” This review synthesizes recent research to propose a precision framework for treating androgenetic alopecia and alopecia areata based on genetic insights and pathway biology, highlighting the roles of androgen-receptor signaling, immune dysregulation, and emerging therapies like regenerative medicine and AI-assisted diagnostics.
November 2025 in “International Journal of Recent Innovations in Medicine and Clinical Research” The abstract does not provide any specific research findings or results, but rather serves as a promotional description for IP Innovative Publication Pvt Limited, highlighting their services and publication offerings in medical journals and related fields from Delhi, India.
November 2025 in “Frontiers in Immunology” This review discusses the role of immune cells in the pathogenesis of alopecia areata and highlights emerging immunomodulatory strategies and novel therapeutic targets aimed at offering more effective and durable treatments for this autoimmune hair loss disorder.
August 2025 in “Archiv Euromedica” This review explored the relationship between alopecia areata and gut microbiota imbalances, noting potential immune dysregulation due to microbiome alterations. It highlighted promising results from fecal microbiota transplantation in treating alopecia universalis, indicating a need for further research into microbiome-targeted therapies.
This study investigated dual TCR Treg cells in mouse tissues, revealing a high proportion and diverse pairing patterns compared to single TCR Tregs, providing insights into their origins and characteristics across different tissue locations.
January 2025 in “Вопросы современной педиатрии” This study discusses the role of Janus kinase inhibitors in treating severe alopecia areata, highlighting their potential to personalize treatment and improve patient quality of life, while addressing concerns about disease relapse after stopping treatment and the safety of long-term use.
In this study, researchers analyzed over 5,000 T cells per sample using scRNA+TCR-seq technology and found that dual TCR Tregs are present in high proportions across various mouse tissues, showing unique TCR pairing patterns, V(D)J usage, and mRNA expression compared to single TCR Tregs.
September 2024 in “Archives of Medical Science” Alopecia areata is linked to immune system differences, with specific biomarkers like CXCL9 and CXCL10 being key for diagnosis and potential treatment targets.
April 2024 in “bioRxiv (Cold Spring Harbor Laboratory)” In a keratinocyte-specific knockout mouse model, this study found that deleting GRK2 disrupted hair follicle homeostasis, causing cyst-like structures, abnormal growth patterns, and eventual hair loss, suggesting potential links to immune-mediated alopecias.
December 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” This study found that AP-2α and AP-2β transcription factors are crucial for maintaining adult skin homeostasis, with their inactivation in keratinocytes leading to impaired differentiation, hair abnormalities, and inflammation, highlighting their key regulatory roles.
September 2023 in “Frontiers in medicine” This review suggests that the mTOR signaling pathway may play a significant role in hair follicle health by influencing the effects of Vitamin D receptor deficiency, potentially contributing to hair follicle damage and related hair loss conditions.
August 2023 in “Sabuncuoglu Serefeddin Health Sciences” This study investigated genetic markers for alopecia areata in the Turkish population, finding that the CT60 polymorphism might be linked to increased susceptibility, while no such association was found for the +49AG polymorphism; further studies are needed to confirm these findings.
August 2023 in “Physician's journal of medicine” This review provides a detailed overview of Hashimoto thyroiditis, discussing its epidemiology, risk factors, genetic and environmental contributors, clinical presentations, diagnostic methods, and treatment options, emphasizing the importance of personalized treatment plans due to varied causes and symptoms.
January 2023 in “Åbo Akademi University Research Portal” This study found that vimentin is essential for proper wound healing and cell growth by influencing EMT signaling and mTOR activity in mice.
October 2021 in “Research Square (Research Square)” This study found that gene expression patterns can effectively distinguish the cashmere growth cycle stages and highlight molecular pathways, suggesting melatonin's role in regulating cashmere growth in Inner Mongolian goats.
June 2021 in “Research Square (Research Square)” This study reports that melatonin influences gene expression related to cashmere growth cycles in Inner Mongolian cashmere goats, potentially aiding in understanding and enhancing cashmere yield through molecular regulation.
April 2021 in “Sohag Medical Journal” This review outlines the proposed theories behind the development of alopecia areata, emphasizing the autoimmune process involving lost immune privilege in hair follicles, and stresses the need to pinpoint specific pathogenic mechanisms for potential treatments.
February 2021 in “Journal of pharmaceutical and biological sciences” This article reviews multiple treatments for alopecia areata, highlighting their variable efficacy and safety without any being curative; it reports no new clinical findings.
This chapter reviews the presence and roles of stem cells in various body systems, focusing on their lifelong function in animals and humans, and reports no new experimental findings.
January 2014 in “Durham e-Theses (Durham University)” In this study, the activation of Notch1 signaling in keratinocytes was found to play a key role in recruiting immune cells and facilitating skin repair after injury.
123 citations
,
September 1987 in “JAMA” This study observed that patients receiving IL-2 immunotherapy developed a skin eruption characterized by burning and pruritus, which resolved shortly after stopping the infusion, suggesting that IL-2 mediated these effects.
November 2025 in “The Journal of Immunology” In a murine model of alopecia areata, this study observed that the IL-2 fusion protein HCW9302 helped prevent disease development by expanding regulatory T cells and reducing disease-causing effector T cell infiltrates, suggesting potential for using IL-2 fusion proteins in alopecia areata treatment.
July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
40 citations
,
July 2015 in “Kidney International” This study found that blocking interleukin-3 improved lupus nephritis symptoms in MRL/Ipr mice, suggesting IL-3 may play a role in the disease's progression.
6 citations
,
January 2022 in “Lara D. Veeken” This narrative review discusses the role and importance of rheumatologists in managing autoimmune interstitial lung disease and emphasizes the need for enhanced collaboration with respiratory physicians to improve diagnosis, management, and outcomes; no new clinical results are reported.
April 2023 in “Journal of Investigative Dermatology” This study found that the oral IRAK4-inhibitors BAY 1834845 and BAY 1830839 reduced skin inflammation and systemic inflammatory responses in healthy volunteers, showing similar pharmacodynamic effects to prednisolone when challenged with topical imiquimod and intravenous LPS.